Remove 2023 Remove Biopharma Remove Biotechnology
article thumbnail

Top 10 Strategic Imperatives Driving Innovation in AI-Enhanced Drug Discovery and Development

Frost & Sullivan

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% However, the pharma/biopharma industry overall shows stagnant R&D activity. growth from 2023 to 2024. increase from 2022. Total R&D expenditure is approximately $276.81

article thumbnail

Emmes Applauded by Frost & Sullivan for Streamlining Clinical Trials and for Its Competitive Strategies

Frost & Sullivan

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. years, to become a truly global company with a diverse mix of public sector and biopharma clients. SAN ANTONIO, TX.

article thumbnail

JP Morgan Healthcare Conference 2025: Key Growth Opportunities Shaping the Future of Pharma and Biotechnology

Frost & Sullivan

While 2024 saw a 41% decline in aggregate deal value , falling from $222 billion in 2023 to $130 billion, 2025 is poised for a rebound. The post JP Morgan Healthcare Conference 2025: Key Growth Opportunities Shaping the Future of Pharma and Biotechnology appeared first on Frost & Sullivan.